Striverdi Respimat Adverse Reactions

Summary of the safety profile: The most common adverse reactions at the recommended dose were nasopharyngitis, dizziness, hypertension, rash and arthralgia. These were usually mild or moderate in intensity.
Tabulated summary of adverse reactions: The frequencies assigned to the undesirable effects listed as follows are based on the crude incidence rates of adverse drug reactions (i.e. events attributed to olodaterol) observed in the olodaterol 5 microgram dose group (1035 patients), pooled from 6 placebo-controlled, parallel group clinical trials in COPD patients with treatment periods ranging between 4 and 48 weeks.
Frequency is defined using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). (See Table 3.)

Click on icon to see table/diagram/image

Description of selected adverse reactions: Occurrence of rash may be considered a hypersensitivity reaction with STRIVERDI RESPIMAT; as with all topical absorbed medication, other hypersensitivity reactions may develop.
Beta₂-agonist adverse reaction profile: STRIVERDI RESPIMAT is a member of the therapeutic class of long-acting beta₂-adrenergic agonists. Therefore, the occurrence of undesirable effects related to the beta-adrenergic agonist class should be taken into consideration, such as tachycardia, arrhythmia, palpitations, myocardial ischaemia, angina pectoris, hypertension or hypotension, tremor, headache, nervousness, insomnia, dizziness, dry mouth, nausea, muscle spasms, fatigue, malaise, hypokalemia, hyperglycemia and metabolic acidosis.